ILEP organisations should strive for high BCG coverage in communities at risk of leprosy
The central thesis of this paper is that the EPI policy of a BCG vaccination at birth or in the first year of life provides proven partial protection against leprosy and that ILEP organisations should actively encourage government health services to maintain a high coverage. A literature review iden...
Saved in:
Published in | Leprosy review Vol. 78; no. 2; pp. 88 - 101 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Colchester
LEPRA
01.06.2007
British Leprosy Relief Association |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The central thesis of this paper is that the EPI policy of a BCG vaccination at birth or in the first year of life provides proven partial protection against leprosy and that ILEP organisations should actively encourage government health services to maintain a high coverage. A literature review identified 12 case-control studies showing a median vaccine efficacy of 63% (range 20-90%). Two prospective studies and two randomised community trials showed a median efficacy of 70% (range 42-80%). The duration of this partial protection is at least 10-15 years. Studies of the long-term protective effect of BCG vaccination against leprosy have not been conducted. One trial has demonstrated a reduction of tuberculosis incidence up to 40 years after vaccination with BCG. There is a growing consensus that BCG works by 'upgrading' the immune response to M. leprae, moving leprosy cases from the lepromatous end of the Ridley-Jopling classification to the tuberculoid end or even makes it possible for infection to remain subclinical. An analysis of national BCG coverage figures as reported to WHO showed that the global mean coverage increased from 58% in 1980 to 88% in 2003. The absolute number of countries reporting less than 80% coverage has decreased from 78 out of 105 in 1981 to 32 of 157 in 2003. Only four countries reported coverages below 60% in 2003. Twenty of the 53 African countries reported coverages below 80% in 2003 against five of 38 countries in Asia, five of 13 countries in Oceania and two of 27 in Central and South America. Comparison of officially reported national coverage to estimates of coverage from special surveys clearly shows that the national figure may not adequately reflect the local situation. Rural communities often have lower coverage than urban populations. Slum households have lower coverage than non-slum households. Remote areas may not be touched by modem health services. Pockets of low BCG coverage exist in countries where leprosy is endemic and ILEP organisations are active. ILEP organisations can make an impact, not by getting involved in vaccination work directly, but by monitoring the BCG coverage and advocating for adequate provision of MCH services in the communities in which they work. This will reduce the risk of leprosy in children up to 15 years of age, provide a number of other benefits to the mothers and children involved and potentially contribute to a reduction of leprosy incidence on the longer term. If the partial protection imparted by BCG is life-long, adding a consistently high BCG coverage to the usual strategy of early case detection and treatment could result in a halving of the leprosy incidence in 2020. |
---|---|
AbstractList | The central thesis of this paper is that the EPI policy of a BCG vaccination at birth or in the first year of life provides proven partial protection against leprosy and that ILEP organisations should actively encourage government health services to maintain a high coverage. A literature review identified 12 case-control studies showing a median vaccine efficacy of 63% (range 20-90%). Two prospective studies and two randomised community trials showed a median efficacy of 70% (range 42-80%). The duration of this partial protection is at least 10-15 years. Studies of the long-term protective effect of BCG vaccination against leprosy have not been conducted. One trial has demonstrated a reduction of tuberculosis incidence up to 40 years after vaccination with BCG. There is a growing consensus that BCG works by 'upgrading' the immune response to M. leprae, moving leprosy cases from the lepromatous end of the Ridley-Jopling classification to the tuberculoid end or even makes it possible for infection to remain subclinical. An analysis of national BCG coverage figures as reported to WHO showed that the global mean coverage increased from 58% in 1980 to 88% in 2003. The absolute number of countries reporting less than 80% coverage has decreased from 78 out of 105 in 1981 to 32 of 157 in 2003. Only four countries reported coverages below 60% in 2003. Twenty of the 53 African countries reported coverages below 80% in 2003 against five of 38 countries in Asia, five of 13 countries in Oceania and two of 27 in Central and South America. Comparison of officially reported national coverage to estimates of coverage from special surveys clearly shows that the national figure may not adequately reflect the local situation. Rural communities often have lower coverage than urban populations. Slum households have lower coverage than non-slum households. Remote areas may not be touched by modem health services. Pockets of low BCG coverage exist in countries where leprosy is endemic and ILEP organisations are active. ILEP organisations can make an impact, not by getting involved in vaccination work directly, but by monitoring the BCG coverage and advocating for adequate provision of MCH services in the communities in which they work. This will reduce the risk of leprosy in children up to 15 years of age, provide a number of other benefits to the mothers and children involved and potentially contribute to a reduction of leprosy incidence on the longer term. If the partial protection imparted by BCG is life-long, adding a consistently high BCG coverage to the usual strategy of early case detection and treatment could result in a halving of the leprosy incidence in 2020. |
Audience | Academic |
Author | OGBEIWI, Osahon I VELEMA, Johan P |
Author_xml | – sequence: 1 givenname: Johan P surname: VELEMA fullname: VELEMA, Johan P organization: Evaluation & Monitoring Network, The Leprosy Mission International, United States – sequence: 2 givenname: Osahon I surname: OGBEIWI fullname: OGBEIWI, Osahon I organization: African Monitoring & Evaluation Service, The Leprosy Mission International, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18973446$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17824479$$D View this record in MEDLINE/PubMed |
BookMark | eNpt0c1LHDEYB-BQLHXVnnovgVIvZab5mnwcdbEqLOihQm8hm0120mYmNpkR_O8b3QUVSg4J4XkT3t97BA7GNDoAPmHUMkEE_x5zK2RLWinfgQXBnDRSInEAFoiirhEdlofgqJTfCFGMFf0ADrGQhDGhFuDX9eriFqa8NWMoZgppLLD0aY4bWKYcHhz0KcM-bHt4vryENj24bLYOhrGeh2EewxRcgWaCOZQ_MHkY3X1O5fEEvPcmFvdxvx-Dux8XP5dXzerm8np5tmos68jUMEzWylsvmLKUKiT9mnOupMLSekQ7Li3zlm-UUtauqSICO-oE9p3sfEX0GJzu3q2__p1dmfQQinUxmtGluWguSYe4FBV-2cGtiU6H0acpG_uE9RnmigtFEKmq_Y-qa-OGYGvwPtT7NwWnrwp6Z-LUlxTn5yjfwm87aGs8JTuv73MYTH7UGOnnQeqYtZCaaPnU1ud9W_N6cJsXu59cBV_3wBRros9mtKG8OKkEZYzTf2Q5pKA |
CODEN | LEREAA |
CitedBy_id | crossref_primary_10_1586_edm_12_55 crossref_primary_10_1586_erv_09_161 crossref_primary_10_1111_j_1365_3083_2011_02510_x crossref_primary_10_4103_jfmpc_jfmpc_478_20 |
ContentType | Journal Article |
Copyright | 2007 INIST-CNRS COPYRIGHT 2007 British Leprosy Relief Association |
Copyright_xml | – notice: 2007 INIST-CNRS – notice: COPYRIGHT 2007 British Leprosy Relief Association |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.47276/lr.78.2.88 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2162-8807 |
EndPage | 101 |
ExternalDocumentID | A169679202 10_47276_lr_78_2_88 17824479 18973446 |
Genre | Journal Article Review |
GroupedDBID | --- 29L 2WC 36B 53G 5GY 5VS AAFWJ AAWTL ABDBF ABPTK ADBBV AEGXH AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS BAWUL DIK E3Z EAD EAP EAS EBD EMB EMK EMOBN ESX F5P FRP GROUPED_DOAJ GX1 IAO IHR IHW INH INR IQODW ITC KQ8 M~E OK1 P2P P6G PV9 RNS RZL SV3 TR2 TUS W2D XSB ZXP CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c452t-412b9fcf749c33908fb66698918cf03568c4fc6d999ccb39271e3e71f585f9183 |
ISSN | 0305-7518 2162-8807 |
IngestDate | Fri Aug 16 07:07:33 EDT 2024 Tue Nov 19 21:40:25 EST 2024 Tue Nov 12 23:43:42 EST 2024 Tue Aug 20 21:59:59 EDT 2024 Fri Aug 23 03:04:17 EDT 2024 Sat Sep 28 07:52:19 EDT 2024 Sun Oct 22 16:07:20 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Infection Skin disease Dermatology BCG Risk factor Bacteriosis Leprosy Tropical medicine Risk Coverage Mycobacterial infection Community |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c452t-412b9fcf749c33908fb66698918cf03568c4fc6d999ccb39271e3e71f585f9183 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
OpenAccessLink | https://doi.org/10.47276/lr.78.2.88 |
PMID | 17824479 |
PQID | 68250687 |
PQPubID | 23479 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_68250687 gale_infotracmisc_A169679202 gale_infotracacademiconefile_A169679202 gale_healthsolutions_A169679202 crossref_primary_10_47276_lr_78_2_88 pubmed_primary_17824479 pascalfrancis_primary_18973446 |
PublicationCentury | 2000 |
PublicationDate | 2007-06-01 |
PublicationDateYYYYMMDD | 2007-06-01 |
PublicationDate_xml | – month: 06 year: 2007 text: 2007-06-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Colchester |
PublicationPlace_xml | – name: Colchester – name: England |
PublicationTitle | Leprosy review |
PublicationTitleAlternate | Lepr Rev |
PublicationYear | 2007 |
Publisher | LEPRA British Leprosy Relief Association |
Publisher_xml | – name: LEPRA – name: British Leprosy Relief Association |
SSID | ssj0031193 |
Score | 1.7784674 |
SecondaryResourceType | review_article |
Snippet | The central thesis of this paper is that the EPI policy of a BCG vaccination at birth or in the first year of life provides proven partial protection against... |
SourceID | proquest gale crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 88 |
SubjectTerms | Bacterial diseases BCG Vaccine - administration & dosage Biological and medical sciences Case-Control Studies Dermatology Developing Countries General aspects Human bacterial diseases Humans Immunization Schedule Incidence Infectious diseases Leprosy Leprosy - prevention & control Medical sciences Prospective Studies Randomized Controlled Trials as Topic Religious Missions - organization & administration Tropical bacterial diseases |
Title | ILEP organisations should strive for high BCG coverage in communities at risk of leprosy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/17824479 https://search.proquest.com/docview/68250687 |
Volume | 78 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQkRASQrxZKMUHJA6rLHk4tnMsVWlBvA4t2pvleO220pKtNqkq9dczEzvJpoB4XKKVY6-9ns_2jPebGUJeGZMsGBjHkRV2ETHNeSSZjaMSDqtUuNxa3Ub7_MwPj9mHeT4fso223iVNOTNXv_Qr-R-pQhnIFb1k_0Gy_ZdCAXwG-cITJAzPv5Lx-4_7X0NepkDKmdanmLMaXUC6eN4YkHj6du9gapCtiRQdTz1HvxCMporujB3BfGlhQ63HTtK-KPi49HeyJ6U9u2yZAF9qfQoQ6m9fv8FB9l0Hmi9usaOLBTEQoPztWQiq1HWDFGnrfkJN8L2K8wj_wNncV4XcwE-6sUn6PH7X924GmhTeIyzXMyFn6czXGkfIvnZy9XzC3YQXXBQpRhW9iSERMYvCwbwn-2RJ4sMvd-P0npptl2-GDke6STih75zrGlaL82lOfm-HtPrI0T1yNxgSdNej4j65YasH5NanQJV4SOYIDjoCB_XgoB4cFMBBERwUwEE7cNCzim6Ag-qGIjjoytEAjkfk-N3-0d5hFNJoRIblaROxJC0LZ5xghcmyIpauBJu1kEUijYuznEvDnOELMBWMKUFfFonNrEgcWJIOKmWPyVa1quxTQhlDhc-ahS5hMQsGtqmMueGgOGsDzSaw-MMEqnMfLUWBldnOs1qulZAqVVJOyEucXOVdffuVqAYxTsjrtgYCpFlro4OzCAwD45WNam6PasLuaEavd0YCHIYlC5ExxmEsnUQVtkXOYWVXF7XiEswDLsWEPPGCHtqCWs2YKJ798Xc8J7eHpbVNtpr1hX0BWmxT7rQA_QHV-J4N |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ILEP+organisations+should+strive+for+high+BCG+coverage+in+communities+at+risk+of+leprosy&rft.jtitle=Leprosy+review&rft.au=Ogbeiwi%2C+Osahon+I&rft.au=Velema%2C+Johan+P&rft.date=2007-06-01&rft.pub=British+Leprosy+Relief+Association&rft.issn=0305-7518&rft.volume=78&rft.issue=2&rft.spage=88&rft_id=info:doi/10.47276%2Flr.78.2.88&rft.externalDBID=n%2Fa&rft.externalDocID=A169679202 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7518&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7518&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7518&client=summon |